Segments of Business (Tables)

3 Months Ended

Jun. 30, 2020

Segment Reporting [Abstract]

Schedule of financial information relating to reportable operating segments and reconciliations to the condensed consolidated totals

Financial information relating to the Company’s reportable operating segments and reconciliations to the condensed consolidated totals is as follows:

	Three Months Ended June 30,
(In millions)	2020		2019
Revenues
U.S. Pharmaceutical and Specialty Solutions (1)	$	45,062	$	44,165
European Pharmaceutical Solutions (1)	6,246		6,710
Medical-Surgical Solutions (1)	1,801		1,903
Other	2,570		2,950
Total revenues	$	55,679	$	55,728
Segment operating profit (loss) (2)
U.S. Pharmaceutical and Specialty Solutions (3)	$	608	$	579
European Pharmaceutical Solutions	(10)		5
Medical-Surgical Solutions	89		125
Other	98		141
Subtotal	785		850
Corporate expenses, net (4)	(80)		(175)
Interest expense	(60)		(56)
Income from continuing operations before income taxes	$	645	$	619
Revenues, net by geographic area
United States	$	47,129	$	46,321
Foreign	8,550		9,407
Total revenues	$	55,679	$	55,728

(1)Revenues from services represent less than 1% of the Company’s U.S. Pharmaceutical and Specialty Solutions segment’s total revenues, less than 10% of the Company’s European Pharmaceutical Solutions segment’s total revenues, and less than 2% of the Company’s Medical-Surgical Solutions segment’s total revenues.

(2)Segment operating profit (loss) includes gross profit, net of operating expenses, as well as other income (expense), net, for the Company’s reportable segments and Other.

(3)The Company’s U.S. Pharmaceutical and Specialty Solutions segment’s operating profit for the three months ended June 30, 2020 and 2019 includes credits of $52 million and $15 million, respectively, related to the last-in, first-out (“LIFO”) method of accounting for inventories.

(4)Corporate expenses, net for the three months ended June 30, 2020 includes a net gain of $131 million recorded in connection with insurance proceeds received from the settlement of the shareholder derivative action related to the Company’s controlled substances monitoring program as discussed in Financial Note 13, “Commitments and Contingent Liabilities.” Corporate expenses, net for the three months ended June 30, 2019 includes net settlement gains of $25 million from the Company’s derivative contracts and a settlement charge of $17 million related to the termination of the Company’s defined benefit pension plan.